Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma

Multiple myeloma (MM) is classified as a lymphoproliferative disorder that remains an incurable malignancy despite improved patient survival with new drug therapies. Polymorphisms are essential in determining the effectiveness and outcome of treatments in MM. Despite significant advances, there needs to be more understanding of the underlying biological mechanisms that determine treatment outcomes. studies show that investigating gene polymorphisms involved in drug metabolism, DNA repair, inflammation, and apoptosis pathways can predict the effectiveness of treatment in MM patients. Therefore, these findings emphasize the potential of genetic profiling for predicting treatment outcomes and tailoring treatments to individual genetic profiles, which increases the efficiency and reduces the toxicity of MM treatments.